Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China

BACKGROUND: There are currently few studies on the efficacy and safety of the dual human epidermal growth factor receptor 2 (HER2)-targeted combination of trastuzumab and pertuzumab in second-line or subsequent therapy of metastatic breast cancer (MBC). This study retrospectively demonstrated the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Yu, Peng, Ying, Zhou, Hao, Zhang, Lili, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469119/
https://www.ncbi.nlm.nih.gov/pubmed/36111041
http://dx.doi.org/10.21037/atm-22-3592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469119/
https://www.ncbi.nlm.nih.gov/pubmed/36111041
http://dx.doi.org/10.21037/atm-22-3592

Ejemplares similares